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Immunomodulation
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Abstract
Serum amyloid A1 (SAA1), a major isoform of acute-phase SAA, is a well-known 
precursor of amyloid A (AA) that contributes to secondary amyloidosis with its 
tissue deposition. Acute-phase SAA is also a biomarker of inflammation. Recent 
studies have focused on the roles for acute-phase SAA in the regulation of immunity 
and inflammation. In vitro characterization of recombinant human SAA identified 
its chemotactic and cytokine-like properties, whereas the use of SAA isoform-spe-
cific transgenic and knockout mice has led to the discovery of new functions of SAA 
proteins in host defense and tissue homeostasis. Characterization of SAA-derived 
peptides has shown that fragments of SAA, generated through proteolysis, are 
bioactive and may contribute to a growing list of functions related to inflammation. 
This chapter summarizes recent progress in the studies of acute-phase SAA and its 
fragments in inflammation and immunomodulation.
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1. Introduction
Serum amyloid A (SAA) was identified in early studies as the precursor of amy-
loid A (AA), the tissue deposit of which causes secondary amyloidosis [1–4]. SAA 
was also found as one of the major acute-phase proteins that are produced in large 
quantities by hepatocytes and released to blood circulation in response to trauma, 
infection, late-stage malignancy and severe stress [5, 6]. Extending from these 
early findings, increased levels of SAA were found both in plasma and in injured 
and inflammatory tissues. A large body of literature reports SAA as a biomarker 
in a variety of diseases ranging from acute inflammation, chronic inflammation, 
type-2 diabetes, malignancy and postsurgical complications [7–9]. However, the 
biological functions of SAA remained largely unknown for many years [10] despite 
efforts in it biochemical characterization, gene cloning of its isoforms, studies of 
the interactions between SAA and high-density lipoprotein (HDL), and delinea-
tion of its regulatory activities in inflammation and immunity. The widespread use 
of recombinant human SAA proteins has accelerated the characterization of the 
biological functions of SAA in vitro, but at the same time produced data that are not 
fully compatible with those obtained from in vivo studies. In the past decade, mice 
with genetically altered genes were prepared and their use in a number of diseases 
models has begun to delineate the pathophysiological functions of SAA in vivo. This 
chapter provides an overview of the studies of SAA that have been published and 
summarizes recent findings of the immunomodulatory functions of different SAA 
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proteins. For other functions of SAA, the interested reader is referred to several 
excellent reviews that have been published recently [9, 11–15].
2. SAA and its role in amyloidosis
SAA is the general name of a family of proteins with high sequence homology 
but encoded by distinct genes [16]. Both humans and mice have 4 SAA genes, but 
in human the SAA3 is a pseudogene that does not express [17]. SAA4 is constitu-
tively expressed in both humans and mice. In contrast, the expression of SAA1, 
SAA2 and in mice, SAA3, is highly inducible [18]. These SAA proteins are therefore 
termed acute-phase SAAs based on their induced expression during the acute-phase 
response [18, 19]. The human SAA genes are located on chromosome 11 while the 
mouse SAA genes are found in a cluster on chromosome 7 [20, 21].
At the primary sequence level, the human and mouse SAA proteins share high 
sequence homology (Figure 1), suggesting that these proteins may have similar 
functions although their modes of expression vary. Of note, although mouse SAA3 
has an expression profile different from that of SAA1 and SAA2, its sequence is as 
homologous to human SAA1 as mouse SAA1 and SAA2 (Figure 1). The sequence 
homology suggests that the functions of SAA3, expressed upon induction by 
inflammatory cues in various mouse tissues, may be similar to those of human 
SAA1 and SAA2.
Human SAA1 has been widely studied for its functions. SAA1 was first identi-
fied as a serum component recognized by antibodies raised against the amyloid 
fibril protein known as amyloid A (AA). In one of the studies, antisera were 
prepared against the major nonimmunoglobulin component of secondary amy-
loidosis. The antisera were able to detect a serum component that was present at 
much higher levels in more than half of the pathological samples collected from 
Figure 1. 
Comparison of the amino acid sequence of human and mouse inducible SAA proteins. The amino acid 
sequences of mature SAA protein (without signal peptides) are shown, and identical amino acids are marked 
with asterisks (*). Inset shows the percent of sequence homology between the 3 inducible mouse SAA proteins 
and human SAA1.
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patients compared to only 7% of normal controls [1]. Husby and Natvig found 
that the serum component detected by the antisera against AA was larger and its 
circulation level was increased with age and during pregnancy [2]. The protein 
immuoprecipitated by the antisera was of low molecular weight with similar but 
not identical amino acid composition of the AA fibrils [22]. It was thought that 
AA could be a subunit of the SAA protein [22], which was identified as a cleavage 
product of SAA.
Amyloidosis develops when insoluble amyloid fibrils accumulate in the extra-
cellular space of the tissues and organs in the body. Patients with chronic inflam-
matory diseases may develop AA amyloidosis, also termed secondary amyloidosis 
[23, 24]. SAA as an amyloid protein has the propensity of fibril formation. 
However, how SAA forms fibril is not fully understood. A number of observations 
suggest that SAA produced in inflammatory tissues is endocytosed into macro-
phages [25], where the acidic environment of lysosome promotes fibril formation 
[26]. The small amount of fibril formed is then exocytosed to the cell surface, 
prompting a nucleation-dependent incorporation of additional SAA into fibrils 
[27]. More recent studies have shown that SAA forms stable oligomers at pH of 
3.5–4.5, that are resistant to proteolysis and undergo α-helix to β-sheet conversion. 
The SAA accumulated in lysosomes eventually escape from the cells [28]. Based 
on these studies, AA fibril formation is a biphasic process [27, 29] that involves an 
intracellular phase and an extracellular phase. Proteolysis is involved probably in 
both phases [27, 30]. In the second phase, additional SAA proteins may be recruited 
with nucleation of AA fibrils, and cleavage of SAA may be a post-fibrillogenic 
event [31].
Recent delineation of the crystal structure of human SAA1 provides a structural 
basis for AA amyloidosis [32]. Despite high levels of sequence homology, different 
SAA isoforms have different propensity in forming AA fibrils. Human SAA1.1 has 
a high tendency of amyloidogenicity, whereas SAA2.2 found in the CE/J mice did 
not form amyloid fibrils [33, 34] despite sequence homology as high as 94% with 
SAA1.1. It was found that the structural determinants for amyloidogenicity reside in 
the first 10–15 residues of mature SAA protein [35]. In a more recent study, SAA2.2 
was found to form small fibrils within a few hours, in contrast to the long lag time 
of SAA1.1 that was characteristically oligomer-rich [36]. These fibrils exhibited 
different morphology and the fibrils of SAA1.1 were found to be pathogenic. The 
results of this study suggest that fibrillation kinetics and prefibrillar oligomers of 
different SAA isoforms may determine their pathogenicity even though they all pos-
sess intrinsic amyloidogenicity.
3. Production and characterization of SAA fragments
In AA amyloidosis, the insoluble AA amyloid protein is derived from the proteo-
lytic cleavage of SAA, generating an N-terminal fragment of SAA. In some cases, 
this AA amyloid protein lacks amino acids at both N- and C-terminus compared to 
the full-length SAA. One reported study found that the AA fibril protein purified 
from rheumatoid arthritis patients with secondary amyloidosis contained 2 frag-
ments with residues 1–50 and 1–45 [37]. However, a SAA fragment with residues 
1–76 (or 2–76) was most commonly found in amyloid fibrils, such as those from the 
livers and spleens of patients with familial Mediterranean fever (FMF), tuberculo-
sis, Hodgkin’s diseases and bronchiectasis [24, 38].
In patients with rheumatoid arthritis, higher serum levels of metalloproteinases 
(MMPs)-1, -2, -3 and -9 were detected compared to healthy controls [39, 40], and 
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the production of these enzymes could be stimulated by SAA [41, 42]. Besides, 
these MMPs were shown to cleave SAA and AA amyloid protein in vitro to produce 
various sizes of SAA fragments (see Table 1). In addition to generating the AA 
fragments commonly identified in secondary amyloidosis, MMP-1, -2 and -3 
cleaved SAA into fragments with residues 1–57, 1–51 and 8–55, respectively [43]. 
The spanning region (residues 51–57) contains sites that may be cleaved by all three 
MMPs. In addition, MMP-2 and MMP-3 can also cleave at other residues including 
residues 7–8 (MMP-2 and -3), 16–17 (MMP-3) and 23–24 (MMP-3). In other species 
studied, MMP-1 and -3 are able to cleave rabbit SAA3 at residues 50–57, showing 
conservation between the rabbit SAA3 and human SAA1 [44]. Therefore it was 
suggested that these MMPs might contribute to the pathogenesis of AA amyloidosis 
by generating SAA fragments.
In addition to their roles in AA amyloidosis, SAA-derived fragments may have 
other biological functions. A recent study demonstrated that MMP-9 could rapidly 
cleave human SAA1 within 30 minutes in vitro to produce COOH-terminal frag-
ments, SAA1 (58–104), SAA1 (52–104) and SAA1 (57–104) [46]. These fragments 
account for 50, 30 and 20% of the total cleaved fragments by MMP-9, respectively. 
The synthetic peptides of these fragments failed to induce CXCL8 production 
in human monocytes and diploid fibroblasts, as well as neutrophil chemotaxis; 
however they potentiated CXCL8-induced neutrophil chemotaxis in a dose-
dependent manner via FPR2 [46]. The authors of this report suggested that intact 
SAA first initiates the inflammatory response and induces the release of MMP-9, 
which cleaves SAA and modulates the response of SAA by potentiating activities 
of selected chemokines to prolong the inflammation process. In addition to MMPs, 
Numbers Sources of SAA fragments References
1–2 An AA amyloidosis patient with rheumatoid arthritis [37]
3 Patients with FMF, tuberculosis, Hodgkin’s disease and bronchiectasis [38]
4–6 Degradation products of human SAA with MMP1, MMP2, MMP3 [43]
7–10 Recombinant SAA cleaved with cathepsin B and cathepsin L [45]
11–12 MMP-9 cleaved recombinant SAA1 [46]
13 Chemically synthesized fragment based on bovine serum SAA1 fragment [47]
14 Recombinant protein based on human SAA1 sequence [48]
The table lists known SAA fragments and synthetic peptides that have been identified. References are provided on the 
column to the right.
Table 1. 
Generation of SAA fragments.
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cathepsins, endosomal and lysosomal proteases, were also shown to cleave SAA and 
might also be involved in AA amyloidosis. Cathepsin B was shown to cleave SAA at 
residues 76–77 to produce the most common form of AA found in amyloidosis [49]. 
Another study also reported that both cathepsin B and L completely cleaved SAA, 
and cathepsin B could produce 9 AA amyloid-like proteins; however, cathepsin L 
produced no fragments resembling AA amyloid proteins by cleaving within the 
N-terminus [45]. All amyloid-like SAA fragments described to date have either an 
intact N-terminus or one that only lacks 1–2 amino acids. Elastase and cathepsin 
D that cleave SAA further along the N-terminus can prevent the formation of AA 
amyloid protein [35, 49, 50].
Accumulating evidence suggests that some of the observed biological functions 
of SAA, other than those related to amyloidosis, may be attributed to SAA-derived 
fragments rather than the intact protein. In some of these studies, synthetic pep-
tides based on SAA protein sequence were prepared to verify or identify the poten-
tial functions. SAA-derived peptides with IFNγ-inducing capability were found in 
human rheumatic synovial fluid [51]. An SAA2-derived peptide with chemotactic 
activity for B lymphocytes was found in cow milk [52]. In a recent study, a frag-
ment of SAA1 (46–112) was found in bovine serum and is equivalent to human 
SAA1 (47–104). The synthetic peptides of this fragment failed to directly induce 
chemotaxis and chemokine production (CXCL8 and CCL3) in human neutrophils 
and monocytes, but it synergized with CXCL8 or CCL3 to induce chemotaxis via 
FPR2 [47]. Studies were also conducted to examine potential functions of SAA and 
its peptides in LPS-induced inflammatory response. SAA-derived fragments lacking 
both N- and C-terminal residues were expressed as recombinant proteins and texted 
for their activities in vitro. Fragments such as one with amino acids 11–58 of human 
SAA1 exhibited minimal proinflammatory activity but enhanced ability to induce 
IL-10 expression and to counteract LPS-induced inflammation and lung injury 
[48]. In a recent study, a peptide consisting amino acids 32–47 of human SAA1 was 
found to disrupt the binding of SAA1 to LPS, suggesting the involvement of this 
region of SAA1 in LPS binding [53].
4. The cytokine-like activities of recombinant SAA
Recombinant SAA was used in an early study that identified the SAA protein as 
a chemoattractant for phagocytes [54]. Xu et al. reported that SAA also induced the 
migration and adhesion of lymphocytes [55]. These studies were among the first 
to identify leukocyte-activating activities of the recombinant SAA protein. SAA 
differs from chemokines as it lacks the characteristic cysteine residues that form 
disulfide bonds for structural stabilization. It was not until 2014 when the crystal 
structures of two SAA proteins were solved [32, 56]. The 4-helix bundle structure of 
the SAA monomers and the propensity of forming multimers [32, 56] are strikingly 
different from the known structural properties of chemokines [57].
Studies conducted by Patel et al. [58] and Fulaneto et al. [59] revealed cytokine-
like activities of SAA for its induction of IL-1β, TNFα, IL-1RA and IL-8. Of note, 
the study conducted by Patel and coworkers used both the recombinant human 
SAA (rhSAA) and purified SAA-HDL complex, although they found that the 
cytokine-inducing activity of the SAA-HDL complex was much lower than that of 
rhSAA. These studies were followed by reports that SAA in neutrophils could induce 
IL-8 expression through one of the chemoattractant receptors [60] that also mediates 
anti-inflammatory activities when stimulated by the eicosanoid lipoxin A4 [61, 62]. 
In addition to proinflammatory cytokines, rhSAA was found to stimulate mono-
cyte expression of tissue factor [63]. Injection of rhSAA to mice increased G-CSF 
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production and neutrophil expansion [64]. SAA also induced the expression of 
immunomodulatory cytokines including selective induction of IL-23 over IL-12 [65] 
and the induction of IL-33 expression [66]. The transcription factors NF-κB, IRF4 
and IRF7 have been implicated in SAA-induced gene expression [66, 67]. In addition, 
SAA appears to be involved in epigenetic regulation of gene expression [68].
One of the cellular targets of SAA is macrophages, a major source of cytokines 
and most if not all SAA receptors. Macrophages may be differentiated into M1 or 
M2 phenotypes. Studies have shown that SAA may influence macrophage differ-
entiation. Anthony et al. examined the effects of SAA in vitro, using human blood 
monocytes from chronic obstructive pulmonary disease patients and healthy con-
trols, and in vivo using a mouse model with airway SAA challenge [69]. Their work 
showed that SAA-rendered human monocytes secrete IL-6 and IL-1β concurrently 
with the M2 markers CD163 and IL-10. Moreover, these cells responded to subse-
quent LPS stimulation with markedly higher levels of IL-6 and IL-1β. In the mouse 
model, SAA induced a CD11chigh CD11bhigh macrophage population in a CSF-1R 
signaling-dependent manner, with concurrent inhibition of neutrophilic inflamma-
tion. Sun et al. investigated the potential effect of SAA on macrophage plasticity, 
and found that SAA treatment led to increased expression of macrophage M2 mark-
ers including IL-10, Ym1, Fizz-1, MRC1, IL-1Rn, and CCL17 [67]. Moreover, SAA 
enhanced efferocytosis of mouse macrophages. Silencing IRF4 by small interfering 
RNA abrogated the SAA-induced expression of M2 markers, suggesting a potential 
role for SAA to alter macrophage phenotype and modulate macrophage functions.
SAA has been identified as an endogenous activator of the NLRP3 inflamma-
some, which is critical to the process of pro-IL-1β. Niemi et al. reported that SAA 
provided a signal for pro-IL-1β expression and for inflammasome activation [70]. 
At least 3 SAA receptors, including TLR2, TLR4 and the ATP receptor P2X7, were 
involved. Interestingly, inflammasome activation was dependent on the activity of 
cathepsin B, the expression of which was induced by SAA. Therefore, SAA-induced 
secretion of cathepsin B could facilitate extracellular processing of SAA and develop-
ment of AA amyloidosis. Ather et al. showed SAA3 expression in the lungs of mice 
exposed to mixed Th2/Th17-polarizing allergic sensitization regimens [71]. SAA 
instillation into the lungs elicited pulmonary neutrophilic inflammation and activa-
tion of the NLRP3 inflammasome, thereby promoting IL-1β secretion by dendritic 
cells and macrophages. SAA administered into the lungs also served as an adjuvant 
that sensitized mice to inhaled OVA, promoting IL-17 production from restimulated 
splenocytes and leukocyte influx. Collectively, these findings illustrate a stimulatory 
function of SAA in the induced expression of IL-1β.
5. SAA receptors
It has long been suspected that the diverse functions of SAA are mediated by cell 
surface receptors. Studies conducted in the past 20 years have led to the identification 
of several cell surface receptors for SAA in addition to a number of binding proteins 
(Figure 2). In 1999, Su et al. reported the involvement of formyl peptide receptor 2 
(FPR2, also termed FPRL1 [72, 73]), in the chemotactic activity of SAA [74]. FPR2 
is a G protein-coupled chemoattractant receptor initially identified as a homolog of 
human FPR1 with low-affinity binding of formylated peptide [75–77]. The identifica-
tion of FPR2 as a receptor for SAA is consistent with reports that SAA induces migra-
tion of phagocytes and to a lesser extent, lymphocytes [54, 55]. Subsequent studies 
have shown that a number of biological functions of SAA, ranging from chemotaxis 
and superoxide generation to induced expression of proinflammatory cytokines and 
matrix metalloproteases, are mediated through FPR2 [47, 60, 78–85].
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The identification of cytokine-like activities of recombinant SAA protein 
suggests the involvement of receptors that typically mediate phagocyte cytokine 
production. The finding that SAA selectively induces IL-23 but not IL-12 expression 
suggests a pattern similar to that of Toll-like receptor (TLR)-mediated cytokine 
induction [65]. In 2008, two of the TLRs were identified as SAA receptors. TLR2, 
and more specifically the TLR2-TLR1 heterodimer, was found to mediate SAA-
induced NF-κB activation leading to the expression of several proinflammatory 
cytokines and chemokines [86]. TLR2 is also responsible for SAA-induced neutro-
phil expansion through upregulation of G-CSF [64]. TLR4 was found to mediate 
SAA-induced expression of iNOS and activation of the related signaling pathways 
[87]. Despite differences in primary and high-level structures between SAA and 
the microbial ligands for these receptors, the two TLRs mediate SAA functions 
both in transfected cells expressing the receptors and in vivo [48, 71, 79, 88–92]. 
The identification of the two TLRs as SAA receptors illustrates the possible roles for 
TLRs in detecting host-derived molecules as a mechanism for alerting immune cells 
upon exposure to environmental stress.
RAGE (receptor for advanced glycation end product) is a multiligand immu-
noglobulin superfamily cell surface molecule. In a study of AA amyloidosis, RAGE 
was identified as a receptor of SAA [93]. The expression of RAGE and its interaction 
with SAA coincide with cell stress, and RAGE has been shown to mediate the NF-κB 
activating effect of SAA [93, 94]. SAA also binds to soluble RAGE [63]. NF-κB activa-
tion induced by SAA interaction with RAGE apparently contributed to the expression 
of tissue factor in monocytes through MAP kinase activation. Inhibition of RAGE 
by a RAGE competitor, by soluble RAGE, and by anti-RAGE IgG reduced the SAA-
stimulated tissue factor expression [63]. RAGE is also reported to mediate the proin-
flammatory activity of SAA in uremia-related atherosclerosis, based on a study using 
the Apoe−/− and Ager−/− mice [95]. These studies identify RAGE as an endothelial and 
monocyte-expressed molecule that mediates selected activities of SAA.
Scavenger receptors on macrophages play important roles in the removal of 
debris during tissue injury and in macrophage transport of lipids. The scavenge-
receptor SR-BI has been known for mediating cholesterol efflux, in which SAA 
plays a role [96]. Two independent studies published in the same year reported the 
identification of SR-BI as an SAA receptor [97, 98]. Direct binding assays using 
radiolabeled SAA found its interaction with SR-B1 in cells that express this receptor 
[97]. SR-BI and its human homolog CLA-I mediate SAA uptake and its down-
stream signaling, including the activation of ERK and p38 MAPK that leads to IL-8 
Figure 2. 
SAA receptors. The major receptors of human and mouse SAA proteins and their projected functions are listed. 
Also shown in the figure are selected binding partners of SAA. OmpA, bacterial outer membrane protein a; HDL, 
high-density lipoprotein. Permission from the publisher was obtained for the use of the crystal structure of SAA1 [32].
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expression [98]. A more recent study reported that SR-BII, a splice variant of SR-BI, 
also serves as a SAA receptor for uptake and proinflammatory signaling through 
MAP kinase signaling [99].
The human P2X7 purinergic receptor is an ionotropic receptor found at high 
expression levels in immune cells such as macrophages and microglia. Activation of 
P2X7 receptor by extracellular ATP opens a cation channel, allowing K+ efflux that 
is associated with processing of pro-interleukin IL-1β and IL-18. Christenson et al. 
found that SAA, either recombinant or purified from the plasma of rheumatoid 
arthritis patients, could suppress apoptosis of human neutrophils, an effect abro-
gated by antagonizing the nucleotide receptor P2X7 [100]. Niemi et al. reported 
that the P2X7 receptor plays a role in SAA-mediated activation of NLRP3, thereby 
explaining the involvement of SAA in the processing of pro-IL-1β [70]. However, 
a recently published work indicates that in murine J774 and bone marrow-derived 
macrophages, SAA stimulates IL-1β secretion through a mechanism that depends on 
NLRP3 expression and caspase-1 activity but not the P2X7 receptor [101].
Collectively, published reports have identified several functional receptors that 
mediate SAA signaling. It is likely that these receptors and their downstream signal-
ing pathways have substantial cross-talk that together contributes to the diverse 
immunomodulatory and homeostatic functions of SAA.
Recent studies have shown that recombinant human SAA, which has been widely 
used in in vitro studies throughout the last two decades, has properties that differ 
from those of native SAA purified from human samples [102–104]. The rhSAA differs 
from human SAA1 in two sites, with amino acid substitutions at positions 60 and 
71 in addition to gaining a methionine at the N-terminus. Since the rhSAA is made by 
Escherichia coli expression, the bacterial contaminants in the preparation may contrib-
ute to the observed cytokine-like activity. This is especially a concern because the con-
taminating bacterial products can activate the two TLRs that are known as the SAA 
receptors. A careful analysis of published literature found evidence that both support 
the use of the two TLRs by SAA and detract from the claim. Many of the published 
studies have included controls for LPS contamination, showing that the SAA protein 
is necessary for the reported biological functions. A recent study has shown that the 
bacterial contaminants may not be LPS that acts through TLR4 but lipoproteins that 
activate TLR2 [105]. The study also showed that adding bacterial lipopeptides into 
mammalian cell-expressed SAA1 protein could restore the cytokine-like activity that 
otherwise was missing from the SAA1 protein [105]. It is however unclear how much 
lipoproteins are carried by the E. coli-derived recombinant SAA. The E. coli expres-
sion system has been widely used in the production of reagents including proinflam-
matory cytokines such as TNFα and IL-1β, and there were not previous concerns over 
bacterial product contamination with these cytokines. Whereas the authors attributed 
the previously reported NLRP3 inflammasome-activating property of SAA to bacte-
rial lipoprotein contaminants in the E. coli-derived SAA [105], another recent study 
demonstrated that SAA purified from human samples was able to stimulate NLRP3 
inflammasome activation [101]. Taken together, these findings raise the possibility 
that bacterial contaminants may modify the biological properties of human SAA1 for 
a potent cytokine-inducing effect. Exactly how much bacterial contaminant is associ-
ated with a recombinant human SAA1 is still unknown, but published studies have 
shown that E. coli-produced SAA proteins can be processed to sufficient purity so they 
can form crystals [32, 56]. Moreover, CHO cell-derived SAA in the form of secreted 
Fc fusion protein has been shown to bind to the ectodomain of TLR2 [86]. While the 
contaminating lipoproteins may contribute to the cytokine-inducing activity through 
TLR2, these contaminants have not been known to stimulate the G protein-coupled 
FPR2 that mediates some of the biological activities of SAA [47, 60, 74, 78–85]. Based 
on available data, it is postulated that some of the observed functions of rhSAA are 
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attributable to bacterial contaminants. In vivo studies conducted in various models of 
diseases are therefore important for confirming the biological functions of SAA under 
physiologically relevant conditions.
6. Immunomodulatory functions of SAA in disease models
Since most of the early studies were conducted using cell lines and isolated 
primary cells such as monocytes and neutrophils, these experimental findings are 
now examined in an in vivo setting. An early model created for the in vivo studies 
of SAA employed adenoviral expression of human SAA1, raising the circulatory 
levels of human SAA1 in the infected mice [106]. This approach was used in studies 
of the involvement of SAA1 in lipid metabolism [106] and fibril formation [107]. In 
a more recent study, the same group that created the adenoviral approach found a 
role for SAA3 in atherosclerosis [108].
Transgenic expression of human SAA1 in mice is another approach used in 
studies of the in vivo functions of SAA. Ji et al. reported transgenic expression of 
human SAA1 in mouse liver [89]. These mice exhibited more severe liver injury, 
increased hepatocyte apoptosis, and higher levels of hepatic enzymes than in their 
wildtype controls. After induction of hepatitis, liver infiltration of CD4+ T cells 
and macrophages was also increased more in the transgenic mice than in wildtype 
mice, along with elevated expression of several chemokines. The aggravated liver 
injury, increased hepatocyte apoptosis and elevated levels of hepatic enzymes in the 
transgenic mice were eased with the use of a TLR2 antagonist, suggesting that TLR2 
mediates the effects of the transgenic SAA1. In a more recent study, Cheng et al. 
placed the human SAA1 under an inducible promoter of SR-A receptor, generating 
transgenic mice with elevated local production of SAA1 upon inflammatory stimula-
tion [53]. The transgenic SAA1 was most abundant in mouse lungs and protected 
mice against acute lung injury caused by LPS administration and cecal ligation and 
puncture (CLP). Transgenic expression of SAA1 did not protect mice against acute 
lung injury induced by intratracheal instillation of TNFα. Binding studies showed 
that human SAA1, purified from either E. coli or transfected HEK293 cells, bound to 
LPS and formed a complex that promoted LPS clearance by macrophages. As a result, 
serum endotoxin concentration was significantly reduced in the transgenic mice than 
in their wildtype controls that went through the CLP procedure. Of note, injection of 
a SAA1-derived peptide that disrupted LPS-SAA1 interaction diminished the endo-
toxin-lowering effect in the SAA1 transgenic mice and increased serum endotoxin 
level in wildtype mice after CLP [53]. These findings suggest a mechanism by which 
acute-phase SAA protects host against bacterial infection-induced injury.
SAA gene knockout mice were generate to examine the physiological functions 
of the individual SAA proteins. After observing SAA1 and SAA2 expression in intes-
tinal epithelial cells and conforming their cell-protecting effect in epithelial cell 
line co-cultured with E. coli, Eckhardt et al. examined the effect of Saa1/2 double 
knockout (DKO) in dextran sodium sulfate (DSS) induced colitis model [109]. 
They found that that epithelial expression of SAA1 and SAA2 protected colonic 
epithelium against bacterial infection. A more recent study using Saa3 gene knock-
out mice found that SAA3 is the predominant isoform of inducible SAA proteins 
in colonic epithelium following chemical injury [92]. Compared to wildtype mice, 
Saa3−/− mice exposed to DSS showed more severe damage to the colonic epithelial 
structure, significantly reduced expression of the anti-microbial peptides Reg3β 
and Reg3γ, and reduced lifespan of afflicted mice if not treated. Administration of 
exogenous SAA3 protein or adoptive transfer of SAA3-treated neutrophils par-
tially ameliorated symptoms of DSS-induced colitis in part due to SAA3-induced 
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neutrophil expression of IL-22, a cytokine with epithelia-protection function [110]. 
Together, these results suggest that epithelial expression of SAA1 and SAA2 in 
healthy mice may be important for homeostasis of gut functions including host 
defense, whereas inducible expression of SAA3 serves to combat acute injury to the 
colonic epithelium.
A role for SAA as a mediator of local immune response has been reported 
recently. In a study of segmented filamentous bacteria (SFB) for its involvement in 
mucosal defenses and autoimmune diseases through RORγ+ Th17 cells, Sano et al. 
found that direct contact of SFB with epithelium in the ileum could induce SAA1 
and SAA2 expression and promote local IL-17A expression in RORγ(+) T cells. The 
mechanisms involved an IL-23R/IL-22 circuit and the participation of type 3 innate 
lymphoid cells (ILC3) that secretes IL-22 [111]. Likewise, Atarashi et al. investi-
gated a group of intestinal microbes for their ability to induce Th17 response, and 
found that SFB could stimulate intestinal epithelial cells to generate SAA and ROS, 
creating an amplification loop for sustained production of SAA by both epithelial 
cells and myeloid cells that led to local Th17 response [112]. These findings provide 
direct evidence for the contribution of epithelial SAA to intestinal homeostasis in 
an environment where host interaction with gut microbiota influences the health 
states of individuals.
In addition to studies of the in vivo functions of SAA in innate immunity and 
inflammation, mice with genetically altered SAA genes were used in the investiga-
tion of these acute-phase proteins in animal models of atherosclerosis, osteoclast 
activation, adipogenesis, and neurodegenerative disorders such as Alzheimer’s 
disease. Ahlin et al. generated transgenic mouse model expressing human SAA1 in 
the adipose tissue, and used the hSAA1+/− mice in studies of the effect of SAA1 
on glucose metabolism and insulin resistance [114]. They found no evidence that 
adipose tissue-derived hSAA1 could influence the development of insulin resistance 
or obesity-related inflammation. The potential involvement of SAA in atherogen-
esis was investigated using the Saa1/2 DKO mice in the Apoe−/− background [115]. 
Surprisingly, the absence of Saa1.1 and Saa2.1 did not affect atherosclerotic lesion 
in the ApoE-deficient mice that were fed with Western diets. It was later reported 
that SAA3, instead of SAA1/2, is pro-atherogenic based on experiments using 
adeno-associated virus for overexpression of SAA3 and antisense oligonucleotide- 
mediated suppression of Saa3 expression [108]. Using SAA3 KO mice, Liu et al. 
reported elevated Tau phosphorylation (hyperphosphorylation) compared to 
wildtype mice upon systemic LPS administration. Overexpression of SAA by 
intracerebral injection attenuated tau hyperphosphorylation in the brain, suggest-
ing that SAA3 may be neuroprotective in the mouse AD model [116].
Several studies of the in vivo functions of SAA were conducted in wildtype mice. 
De Santo et al. reported that systemic SAA1 plays a role in the regulation of neutro-
phil plasticity through induction of the anti-inflammatory IL-10 and promotion of 
the interaction of invariant natural killer T cells (iNKT cells) with neutrophils. As a 
result, SAA1 indirectly limits the suppressive activity by diminishing IL-10 produc-
tion and enhancing IL-12 production [113].
Collectively, results from the studies of SAA proteins in mice identified impor-
tant functions of SAA that were previous unknown from in vitro studies. There 
are other functions revealed from the in vivo studies using genetically altered mice 
that are consistent with the in vitro findings. For example, the ability of SAA to 
interact with Gram-negative bacterial wall components [117] is consistent with the 
in vivo findings that SAA1 protects mice against LPS- and CLP-induced acute lung 
injury [53]. The in vivo findings strongly suggest that acute-phase SAA protects 
host against environmental insults such as chemical-induced intestinal epithelial 
injury and bacterial infection. Four of the animal models used in studies of SAA are 
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summarized in Figure 3. Due to page limitation, in vivo studies on SAA functions 
other than those related to immunomodulation are not discussed in this chapter.
7. Conclusion remarks
SAA has emerged from a precursor of AA to a modulator of immunity and 
inflammation. Several developments, including the ability to express recombinant 
SAA proteins, the generation of genetically altered mice expressing SAA transgenes 
or deletion of a specific SAA gene, and the availability of crystal structures of SAA 
proteins, have helped to advance our understanding of SAA for its functions in host 
defense, lipid metabolism, adipogenesis, and neuroprotection. In coming years, 
studies will likely focus on the comparison of SAA functions in vitro to those identi-
fied in vivo, and on the possible modifications and proteolytic processing of newly 
synthesized SAA in order to address several questions that remain unanswered today. 
A better understanding of SAA for its biological functions is expected to benefit 
human health through development of new diagnostic approaches and therapies.
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Figure 3. 
Immunomodulatory functions of SAA in selected mouse models. Left: transgenic expression of human SAA1 in 
the lung tissue protects mice against LPS-induced acute lung injury [53]. The protection is conferred in part 
through SAA binding to LPS, forming a complex that promotes LPS clearance by macrophages. Middle: SAA1 
and SAA2 expressed in epithelium of the ileum serves as a mediator of segmented filamentous bacteria-induced 
local Th17 response [111, 112], contributing to homeostasis of the microenvironment in the intestine [109]. In 
response to acute injury such as dextran sodium sulfate (DSS) treatment, SAA3 is induced in mouse colonic 
epithelium and serves as an inducer for neutrophil IL-22 expression [92]. Right: SAA1-producing melanomas 
induce neutrophil secretion of IL-10 for its suppressive effect. SAA1 also promotes neutrophil interaction with 
invariant natural killer T (iNKT) cells, thereby limiting IL-10 production but enhancing IL-12 production 
[113]. This mechanism may be explored to reduce the immunosuppressive neutrophils and restore tumor-specific 
immunity.
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